Is BELITE BIO, INC (BLTE) Halal?

NASDAQ Healthcare United States $6.0B
✓ HALAL
Confidence: 95/100
BELITE BIO, INC (BLTE) is Halal under 3 of 5 Shariah screening standards, including AAOIFI Standard 21. With a debt ratio of just 0.0% against the AAOIFI threshold of 30%, BELITE BIO, INC comfortably passes the key financial ratio tests. The company operates in the Healthcare sector (Biotechnology), which is not a prohibited industry under Islamic finance principles.

Shariah Screening — 5 Standards

Based on financial data from December 2024

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.0%
/ 30%
2.2%
/ 30%
0.0%
/ 30%
N/A ✓ HALAL
DJIM 0.0%
/ 33%
2.2%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
MSCI 0.4%
/ 33%
95.4%
/ 33%
0.4%
/ 33%
N/A ✗ NOT HALAL
S&P 0.0%
/ 33%
2.2%
/ 33%
0.0%
/ 33%
N/A ✓ HALAL
FTSE 0.4%
/ 33%
95.4%
/ 33%
0.4%
/ 50%
N/A ✗ NOT HALAL

Financial Highlights

EPS
$-2.32
P/B Ratio
7.8
Beta
-1.5
Low volatility
Current Ratio
49.1

Profitability

Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
Return on Equity (ROE) -16.9%
Return on Assets (ROA) -11.3%

Cash Flow & Balance Sheet

Operating Cash Flow-$29M
Free Cash Flow-$29M
Total Debt$537,000
Current Ratio49.1
Total Assets$152M

Price & Trading

Last Close$149.18
50-Day MA$170.38
200-Day MA$112.56
Avg Volume208K
Beta-1.5
52-Week Range
$49.00
$200.00

About BELITE BIO, INC (BLTE)

CEO
Dr. Yu-Hsin Lin M.B.A., Ph.D.
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$6.0B
Currency
USD

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is BELITE BIO, INC (BLTE) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), BELITE BIO, INC is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is BELITE BIO, INC's debt ratio?

BELITE BIO, INC's debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.4%.

What are BELITE BIO, INC's key financial metrics?

BELITE BIO, INC has a market capitalization of $6.0B. Return on equity stands at -16.9%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.